Healthcare entity
Every one of those 1 sits in a single category, market-trends. Spikevax is most often covered alongside Arbutus Biopharma, which appears in 1 of these 1 story. At 7, the average consequence score sits above the same-window beat average of 5.9.
Last mentioned: Mar 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Spikevax is most often covered alongside Arbutus Biopharma, which appears in 1 of these 1 story. At 7, the average consequence score sits above the same-window beat average of 5.9. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. We currently track 1 Healthcare story that mention Spikevax, all published on March 4, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Spikevax. Shared-story counts are live from our verified record — not editorial picks.
Moderna has agreed to pay Roivant Sciences up to $2.25 billion to settle long-standing patent infringement claims regarding the Lipid Nanoparticle (LNP) technology used in its COVID-19 vaccine. The settlement provides a massive capital windfall for Roivant and Arbutus Biopharma while removing a major legal risk for Moderna.
Spikevax is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
